Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04501276
Registration number
NCT04501276
Ethics application status
Date submitted
29/07/2020
Date registered
6/08/2020
Date last updated
31/01/2024
Titles & IDs
Public title
A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients
Query!
Scientific title
A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of ADG116, ADG116 Combined With Toripalimab (Anti-PD-1 Antibody), ADG116 Combined With ADG106 (Anti-CD137 Antibody) in Patients With Advanced/Metastatic Solid Tumors
Query!
Secondary ID [1]
0
0
ADG116-1003
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Advanced/Metastatic Solid Tumors
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - ADG116
Treatment: Drugs - ADG106
Treatment: Drugs - anti PD1 drug
Experimental: Part A : Dose escalation of ADG116 monotherapy -
Experimental: Part B : Dose escalation of ADG116 combined with anti PD1 drug -
Experimental: Part C : Dose escalation of ADG116 combined with ADG106 -
Treatment: Drugs: ADG116
For monotherapy ADG116 (Part A), ADG116 will be administered IV over 60 90 minutes until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.
Treatment: Drugs: ADG106
For the ADG116-ADG106 combination regimen, ADG116 and ADG106 will be administered until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.
Treatment: Drugs: anti PD1 drug
For the ADG116-anti PD1 combination regimen, ADG116 and anti PD1 will be administered until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of participants experiencing dose-limiting toxicities escalating dose levels in adults with advanced / metastatic solid tumors
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
From first dose of ADG116 (Week 1 Day 1) until 21 days
Query!
Primary outcome [2]
0
0
Number of participants with adverse events as assessed by CTCAE v5.0
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
From first dose of ADG116 (Week 1 Day 1) to 28 days post last dose
Query!
Secondary outcome [1]
0
0
Area under the time concentration curve (AUC) from time zero to infinity (AUC0-inf)
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
From first dose (Cycle 1 Day 1, ) until the last dose (up to 2 years)
Query!
Secondary outcome [2]
0
0
Maximum (peak) plasma concentration (Cmax)
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
From first dose (Cycle 1 Day 1,) until the last dose (up to 2 years)
Query!
Secondary outcome [3]
0
0
Time to maximum (peak) plasma concentration (Tmax)
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
From first dose (Cycle 1 Day 1,) until the last dose (up to 2 years)
Query!
Secondary outcome [4]
0
0
Trough plasma concentration (Ctrough)
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
From first dose (Cycle 1 Day 1,) until the last dose (up to 2 years)
Query!
Secondary outcome [5]
0
0
Incidence of ADAs
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
From first dose (Cycle 1 Day 1,) until the last dose (up to 2 years)
Query!
Secondary outcome [6]
0
0
Preliminary evidence of antitumor activity as characterized by objective response rate (ORR), disease control rate (DCR), duration of response (DOR), duration of stable disease, progression free survival (PFS), and overall survival (OS).
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
From first dose of ADG116 (Week 1 Day 1) to 28 days post last dose
Query!
Eligibility
Key inclusion criteria
Patients must meet all of the following inclusion criteria to be eligible for participation
in this study:
1. = 18 years of age at the time of informed consent.
2. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
3. Patients with advanced or metastatic solid tumors, who have progressed after all
standard therapies, or for whom no further standard therapy exists.
4. At least 1 measurable lesion at baseline according to the definition of RECIST v1.1.
5. Adequate organ function.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
• Patients who meet any of the following criteria cannot be enrolled:
1. Pregnant or breastfeeding females.
2. Childbearing potential who does not agree to the use of contraception during the
treatment period..
3. Treatment with any investigational drug within washout period.
4. Grade = 3 immune-related AEs (irAEs) or irAE that lead to discontinuation of prior
immunotherapy.
5. Central nervous system disease involvement
6. History or risk of autoimmune disease.
7. History of life-threatening hypersensitivity or known to be allergic to protein drugs
or recombinant proteins or any ingredients contained in the ADG116 drug formulation.
8. Patients requiring systemic treatment with corticosteroids
9. Patients receiving granulocyte colony stimulating factor (G-CSF), within 14 days prior
to the first dose of the study drug.
10. Any uncontrolled active infections requiring systemic antimicrobial treatment (viral,
bacterial, or other), or uncontrolled or poorly controlled, asthma, chronic
obstructive pulmonary disease (COPD).
11. Major surgery within 4 weeks prior to the first dose of the study drug.
12. Has had an allogeneic tissue/solid organ transplant.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Other
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
23/09/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
15/08/2024
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
72
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Ashford Cancer Centre Research - Kurralta Park
Query!
Recruitment hospital [2]
0
0
Cabrini Hospital - Malvern
Query!
Recruitment hospital [3]
0
0
Macquarie University - Sydney
Query!
Recruitment postcode(s) [1]
0
0
- Kurralta Park
Query!
Recruitment postcode(s) [2]
0
0
- Malvern
Query!
Recruitment postcode(s) [3]
0
0
- Sydney
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Texas
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Adagene Inc
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a Phase 1, open-label, dose escalation study in patients with advanced/metastatic
solid tumors. Study drug, ADG116, is an anti -CTLA-4 fully human monoclonal antibody that
specifically binds to human CTLA-4. ADG106, a fully human ligand-blocking agonistic
anti-CD137 IgG4 mAb, is expected to enhance the activity of activated T cells. The enhanced
antitumor efficacy results observed from the preclinical studies of ADG116 in combination
with ADG106 or anti-PD-1 provided further support to explore such combinations in clinical
settings for better patient responses.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04501276
Query!
Trial related presentations / publications
Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA; National Comprehensive Cancer Network. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385. Epub 2018 Feb 14.
Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007 Feb;7(2):95-106. doi: 10.1038/nrc2051.
Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol. 2012 Sep;23 Suppl 8(Suppl 8):viii6-9. doi: 10.1093/annonc/mds256.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04501276
Download to PDF